Actively Recruiting
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Led by John O. Prior · Updated on 2026-05-11
69
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging. Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of \[68Ga\]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients. The identification of a correlation between \[68Ga\]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.
CONDITIONS
Official Title
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Male or female
- Age 18 years or older
- Patients suspected of cardiac sarcoidosis or immune checkpoint inhibitor induced myocarditis, or patients in their first year after heart transplant
- Receiving standard clinical follow-up at the cardiology department in CHUV
You will not qualify if you...
- No signed written informed consent
- Age under 18 years
- Claustrophobia
- Myocardial ischemia diagnosed by non-invasive perfusion test or coronarography (for cardiac sarcoidosis and myocarditis groups)
- Clinically unstable cardiovascular conditions, including unstable brady-tachyarrhythmia, severe symptomatic low or high blood pressure, or cardiogenic shock
- Pregnant or breastfeeding women
- Intention to become pregnant during the study (cardiac sarcoidosis group)
- Previous participation in this study
- Moderate to severe kidney problems with contraindication to gadolinium use (cardiac sarcoidosis and myocarditis groups)
- Investigator, family members, employees or dependents enrolled
- Any disease or condition that may interfere with study objectives as judged by the investigator
- Insufficient understanding of the project language or inability to consent or follow procedures
- Patient refuses to be informed about incidental findings
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland, 1011
Actively Recruiting
Research Team
J
John O Prior, MD, PhD
CONTACT
C
Christel Kamani, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here